Navigation Links
The MDS Foundation supports the FDA's decision to expand vidaza label to include survival data
Date:8/25/2008

Crosswicks, NJ (August 22, 2008) The Myelodysplastic Syndromes (MDS) Foundation supports the decision by the U.S. Food & Drug Administration (FDA) to extend the label for VIDAZA (azacitidine) to include data from the AZA-001 clinical trial. Results from the trial found that azacitidine is the only agent which has been shown to extend survival in MDS patients.

Data from the AZA-001 trial was recently presented at this year's American Society of Clinical Oncology (ASCO) Annual Meeting and found that azacitidine nearly doubled the two-year survival rate for higher-risk MDS patients compared to conventional care regimens (CCR) with a mean survival of 24.5 months compared to 15 months for patients who received CCR.

"We are extremely encouraged by the results of the AZA-001 trial which for the first time showed that survival could be extended for patients with higher-risk MDS," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "Roughly 30 percent of patients diagnosed with MDS will progress to acute myeloid leukemia (AML), but treatment with VIDAZA significantly delays this progression. VIDAZA not only has great survival data in MDS, but can also prevent progression to AML."

Results from the trial also showed that azacitidine reduced the need for blood transfusions in higher-risk MDS patients with nearly half (45 percent) of patients who were transfusion dependent at the start of the trial achieving transfusion independence.

Additionally, azacitidine was shown to delay the progression of MDS to acute myeloid leukemia (AML). Roughly 30 percent of patient diagnosed with MDS will progress to AML. The delay in progression is especially significant because patients with MDS are typically over the age of 65. According to the National Institute of Health, in this patient group, the average 5-year survival rate after diagnosis with AML is only approximately four percent.

MDS is a primary neoplasm of the bone marrow that is more prevalent than any of the leukemias. MDS affects the function of blood cells, either red blood cells, white blood cells or platelets. The incidence of MDS is underestimated.


'/>"/>

Contact: Kathy Heptinstall
800-637-0839
Weber Shandwick Worldwide
Source:Eurekalert

Related biology news :

1. New York Stem Cell Foundation announces third annual Translational Stem Cell Research Conference
2. Michael J. Fox Foundation PD Therapeutics Conference
3. Michael J. Fox Foundation Funds $1.1 Million for Cutting-edge Approaches to Parkinsons Disease
4. W.M. Keck Foundation grant funds reproductive science research
5. W.M. Keck Foundation announces 2008 class of Distinguished Young Scholars in Medical Research
6. Michael J. Fox Foundation awards $2.4M for validation of therapeutic targets for Parkinsons
7. Glenn Foundation for Medical Research commits $5 million to study aging
8. BBVA Foundation Awards for Biodiversity Conservation
9. The Parkinsons Disease Foundation awards $950,000 in seed grants
10. The AGA Foundation invests in gastroenterologys future
11. European Science Foundation aims to strengthen regenerative medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... ... April 27, 2017 , ... ... rebrand and a name change to Fluence Analytics. , Fluence Analytics ... of polymer and biopharmaceutical manufacturing processes and R&D applications. The company’s patented ...
(Date:4/27/2017)... Tenn. , April 27, 2017  Pendant Biosciences, ... developing innovative surface modification and drug delivery technologies, today ... Johnson Innovation, JLABS @ Toronto . ... Executive Officer of Pendant Biosciences, noted, "We are excited ... Toronto community, and are honored to be ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... with NASA to showcase the future of deep space exploration and inspire space ... and Orion spacecraft and includes a guest appearance by former Shuttle Astronaut Don ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... demonstrating its new Bioflash MailGuardtm mail security screening solution at the National Postal ... Bioflash MailGuard system provides a fast, highly accurate, easy to use and low ...
Breaking Biology Technology: